Rapid Elaboration of Fragments into Leads Applied to Bromodomain-3 Extra-Terminal Domain.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
27 04 2023
Historique:
medline: 3 5 2023
pubmed: 19 4 2023
entrez: 18 4 2023
Statut: ppublish

Résumé

The development of low-affinity fragment hits into higher-affinity leads is a major hurdle in fragment-based drug design. Here, we demonstrate the Rapid Elaboration of Fragments into Leads (REFiL) by applying an integrated workflow that provides a systematic approach to generate higher-affinity binders without the need for structural information. The workflow involves the selection of commercial analogues of fragment hits to generate preliminary structure-activity relationships. This is followed by parallel microscale chemistry using chemoinformatically designed reagent libraries to rapidly explore chemical diversity. After a fragment screen against bromodomain-3 extra-terminal (BRD3-ET) domain, we applied the REFiL workflow, which allowed us to develop a series of ligands that bind to BRD3-ET. With REFiL, we were able to rapidly improve binding affinity > 30-fold. REFiL can be applied readily to a broad range of proteins without the need for a structure, allowing the efficient evolution of low-affinity fragments into higher-affinity leads and chemical probes.

Identifiants

pubmed: 37071570
doi: 10.1021/acs.jmedchem.3c00137
doi:

Substances chimiques

Proteins 0
Ligands 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5859-5872

Auteurs

Luke A Adams (LA)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia.

Lorna E Wilkinson-White (LE)

Sydney Analytical Core Research Facility, University of Sydney, Camperdown, NSW 2006, Australia.

Menachem J Gunzburg (MJ)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia.

Stephen J Headey (SJ)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia.

Biswaranjan Mohanty (B)

Sydney Analytical Core Research Facility, University of Sydney, Camperdown, NSW 2006, Australia.

Martin J Scanlon (MJ)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia.

Ben Capuano (B)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia.

Joel P Mackay (JP)

School of Life and Environmental Sciences, University of Sydney, Camperdown 2006, NSW, Australia.

Bradley C Doak (BC)

Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville 3052, VIC, Australia.

Articles similaires

Databases, Protein Protein Domains Protein Folding Proteins Deep Learning
Alzheimer Disease Humans Regression Analysis Quantitative Structure-Activity Relationship Drug Design
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics
1.00
Saccharomyces cerevisiae Lysine Cell Nucleolus RNA, Ribosomal Saccharomyces cerevisiae Proteins

Classifications MeSH